[关键词]
[摘要]
目的 观察注射用丹参多酚酸联合替罗非班对急性进展性脑梗死患者的NIHSS评分和mRS评分的影响。方法 选择2017年1月-2019年12月在郑州市第一人民医院治疗的急性进展性脑梗死患者82例作为研究对象。将患者依据入组时间随机分为对照组和观察组,每组各41例。对照组前30 min静脉泵入负荷剂量盐酸替罗非班氯化钠注射液,0.4 μg/(kg·min),后给予0.1 μg/(kg·min)的低剂量维持24 h。观察组在对照组治疗的基础上静脉滴注注射用丹参多酚酸,0.13 g加入到250 mL氯化钠注射液中,1次/d。两组均治疗14 d。观察并比较两组患者的美国国立卫生研究院卒中量表评分(NIHSS)、改良Rankin量表评分(mRS)和不良反应情况。结果 治疗后,两组NIHSS评分均显著下降,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,观察组NIHSS评分明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗90 d后随访,观察组mRS评分总有效率为82.9%,显著高于对照组的61.0%,两组比较差异具有统计学意义(P<0.05)。两组患者均未出现严重不良反应,在肝功能异常、血小板减少、牙龈出血、皮肤黏膜出血等方面,差异无统计学意义。结论 注射用丹参多酚酸联合替罗非班能够减轻急性脑进展性梗死患者神经缺损症状,改善预后,且不良反应轻,安全性好,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To observe the effect of Salvianolic Acids for Injection combined with tirofiban on NIHSS and mRS scores in patients with acute progressive cerebral infarction. Methods A total of 82 patients with acute progressive cerebral infarction treated in the First People Hospital of Zhengzhou from January 2017 to December 2019 were selected as study subjects. The patients were randomly divided into the control group and the observation group according to the enrollment time, with 41 cases in each group. Patients in the control group were injected intravenously for Tirofiban hydrochloride Sodium Chloride Injection with a loading dose of 0.4 μg/(kg·min) in the first 30 min, and then 0.1 μg/(kg·min) was given as a low dose for 24 h. Patients in the observation group were iv administered with Salvianolic Acids for Injection on the basis of control group, 0.13 g was added to 250 mL sodium chloride injection, once daily. Both groups were treated for 14 d. After treatment, NIHSS score, mRS score, and adverse reactions were observed and compared in two groups. Results After treatment, NIHSS score in two groups were decreased significantly, and the difference before and after treatment in the same group was statistically significant (P<0.05). After treatment, the NIHSS score in the observation group was significantly lower than that in the control group, and the difference between two groups was statistically significant (P<0.05). After 90 days of follow-up, the total effective rate of mRS score in the observation group was 82.9%, which was significantly higher than 61.0% in the control group, and the difference between two groups was statistically significant (P<0.05). There were no serious adverse reactions in two groups, and there were no statistically significant differences in liver function abnormalities, thrombocytopenia, gingival bleeding, skin mucosal bleeding in two groups. Conclusion Salvianolic Acids for Injectioncombined with tirofiban can alleviate nerve defect symptoms and improve prognosis in patients with acute progressive cerebral infarction, with mild adverse reactions and good safety, and certain clinical application value.
[中图分类号]
R971
[基金项目]